Physician profile
Jennifer D Holman
NPI 1447354626
$622,379.09
in general payments reported to CMS, 2019-2025
41 companies · $74K in 2025
The $74K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157K · 2020: $103K · 2021: $65K · 2022: $86K · 2023: $55K · 2024: $83K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $169K · Travel and Lodging: $32K · Food and Beverage: $9,421 · Consulting Fee: $1,988 · Education: $24.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,082.29 |
| Travel and Lodging | $31,627.98 |
| Food and Beverage | $9,420.54 |
| Consulting Fee | $1,987.50 |
| Education | $24.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $419,055.16 | 2019-2025 | |
| Galderma Laboratories, L.P. | $108,303.93 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Lilly USA, LLC | $84,372.47 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $2,706.00 | 2019-2024 | Tremfya |
| Allergan, INC. | $1,740.56 | 2019-2022 | |
| Genzyme Corporation | $1,473.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $894.12 | 2019-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $769.90 | 2024-2025 | Daxxify |
| Ucb, INC. | $503.69 | 2019-2025 | Bimzelx |
| Solta Medical, A Division of Bausch Health US, LLC | $416.94 | 2019 | |
| Leo Pharma INC. | $330.80 | 2019-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $311.94 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $236.95 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| Novartis Pharmaceuticals Corporation | $225.68 | 2019-2023 | |
| Pfizer INC. | $206.92 | 2021-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $88.36 | 2025 | Vtama, Nexplanon |
| Medtronic, INC. | $76.79 | 2022 | |
| Incyte Corporation | $67.03 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.68 | 2022-2023 | Spevigo |
| Sanofi-Aventis U.S. LLC | $48.61 | 2021 | |
| Janssen Scientific Affairs, LLC | $44.31 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $39.32 | 2021-2022 | |
| Kerecis Limited | $38.73 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Dermavant Sciences, INC. | $33.37 | 2022-2024 | Vtama |
| Almirall LLC | $33.35 | 2019-2021 | |
| Sientra, INC. | $33.26 | 2019 | |
| Dusa Pharmaceuticals, INC. | $31.18 | 2019 | |
| Kyowa Kirin, INC. | $28.93 | 2021-2022 | |
| Sandoz INC. | $21.10 | 2020 | |
| Strata Skin Sciences, INC. | $20.44 | 2020 | |
| Aclaris Therapeutics, INC. | $19.29 | 2019 | |
| Botanix Sb INC | $18.18 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $15.88 | 2021 | |
| Genentech USA, INC. | $15.18 | 2021 | |
| Smith+Nephew, INC. | $15.17 | 2024 | Grafix Pl |
| Krystal Biotech INC | $14.28 | 2025 | Vyjuvek |
| Merz North America, INC. | $13.72 | 2021 | |
| Amgen INC. | $13.62 | 2021 | |
| Kci USA, INC. | $13.59 | 2020 | |
| Mission Pharmacal Company | $13.41 | 2021 | |
| Epi Health, LLC | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.